Inventor · Arceau, FR

Nathalie Piccardi

25Patents
6h-index
11Co-inventors
62Inventor score

Filing activity: Nov 14, 2001 → Jan 16, 2018

Most-cited inventions

PatentTitleAreaCited byStatus
US7897579B2 Use of a compound comprising D-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases Human Necessities 10 Expired
US7589121B2 Use of furan alkyls for preparing a drug for treating obesity and cosmetically treating overweight Human Necessities 10 Expired
US7833554B2 Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency Human Necessities 8 Active
US9023810B2 Use of a compound comprising D-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases Human Necessities 8 Active
US8349377B2 Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency Human Necessities 8 Active
US9089576B2 Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency or oxidative stress or skin ageing or dry skin Human Necessities 8 Active
US7238377B2 Use of an oil of the gourd family for inhibiting 5 alpha-reductase activity Human Necessities 5 Expired
US8734865B2 Lupin total extract consisting of a lupin sugar extract and a lupin peptide extract, method for the production and use thereof Human Necessities 1 Active
US7511010B2 Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting Langerhans' cell migration Human Necessities 1 Expired
US9682025B2 Combination of active agents for oral administration for improving the quality of nails Human Necessities 0 Active
US8653117B2 Composition comprising at least one oxazoline to inhibit migration of langerhans cells, and uses thereof Human Necessities 0 Active
US9901535B2 Use of a combination of taurine or a derivate thereof and a grape extract for improving the quality of the nails Human Necessities 0 Active
US7872043B2 Use of furan alkyls for a cellulite cosmetic treatment Human Necessities 0 Expired
US10548834B2 Composition intended for an oral administration based on polyunsaturated fatty acid and vitamin D for improving hair quality Human Necessities 0 Active
US8722023B2 Depigmenting or brigthening cosmetic composition comprising at least one oxazolin as an active ingredient Human Necessities 0 Active
US11147302B2 Use of a combination of taurine or a derivate thereof and a grape extract for improving the quality of the nails Human Necessities 0 Active
US7763647B2 Topical solution containing a chromane or chromene derivative Human Necessities 0 Expired
US8236836B2 Composition comprising at least one oxazoline for inhibiting langerhans cell migration, and uses thereof Human Necessities 0 Active
US10022315B2 Oral composition for reinforcing skin tolerance following topical administration of a retinoid compound Human Necessities 0 Active
US7629371B2 Cosmetic use of a composition containing at least one oxazoline, serving as an active substance, as a slimming product and/or for preventing and/or treating cellulite Human Necessities 0 Expired
US8747815B2 Use of a cosmetic of pharmaceutical composition, comprising a lupeol-rich extract as an active ingredient for stimulating the synthesis of heat shock proteins Human Necessities 0 Active
US8859617B2 Use of furan alkyl for preparing an antidiabetic drug Human Necessities 0 Active
US9642786B2 Use of a combination of at least one polyunsaturated fatty acid and at least one carotenoid, for improving the quality of the nails Human Necessities 0 Active
US7473434B2 Maca extract and cosmetic composition containing such an extract Human Necessities 0 Expired
US8304453B2 Composition comprising at least one alkanolamide to inhibit migration of langerhans cells and uses therof Human Necessities 0 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.